De-pei S. Wu

188 Shizi Street
Suzhou, 215006, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 302 publications

Analysis of Clinical Features of Newly Diagnosed Multiple Myeloma Complicated with Light Chain Amyloidosis

Analysis of Clinical Features of Newly Diagnosed Multiple Myeloma Complicated with Light Chain Amyloidosis

Journal: Zhongguo shi yan xue ye xue za zhi

Published: August 03, 2026

Validation of the Predictive Ability of IMWG, IMPEDE and SAVED Thrombosis Risk Stratification Systems for Venous Thromboembolism in Chinese Multiple Myeloma Patients

Validation of the Predictive Ability of IMWG, IMPEDE and SAVED Thrombosis Risk Stratification Systems for Venous Thromboembolism in Chinese Multiple Myeloma Patients

Journal: Zhongguo shi yan xue ye xue za zhi

Published: August 03, 2026

Clinical Study on the Transition of First-Line Bortezomib Intole- rance to Carfilzomib in the Treatment of Multiple Myeloma

Clinical Study on the Transition of First-Line Bortezomib Intole- rance to Carfilzomib in the Treatment of Multiple Myeloma

Journal: Zhongguo shi yan xue ye xue za zhi

Published: March 18, 2026

Impact of Concurrent Genetic Alterations on Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in TP53-Mutated Acute Myeloid Leukemia and Myelodysplastic Syndromes.

Impact of Concurrent Genetic Alterations on Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in TP53-Mutated Acute Myeloid Leukemia and Myelodysplastic Syndromes.

Journal: Cancer letters

Published: January 31, 2026

Rbm5 sustains leukemia stem cells through a Myc-driven transcriptional circuitry.

Rbm5 sustains leukemia stem cells through a Myc-driven transcriptional circuitry.

Journal: Leukemia

Published: December 18, 2025

Measurement of the Cosmic Ray Nickel Energy Spectrum from 10 GeV/n to 2 TeV/n with the DAMPE Space Mission.

Measurement of the Cosmic Ray Nickel Energy Spectrum from 10 GeV/n to 2 TeV/n with the DAMPE Space Mission.

Journal: Physical review letters

Published: December 15, 2025

Who is the best allogeneic hematopoietic stem cell transplant donor for severe aplastic anemia? Data from the Chinese Bone Marrow Transplantation Registry Group (CBMTRG).

Who is the best allogeneic hematopoietic stem cell transplant donor for severe aplastic anemia? Data from the Chinese Bone Marrow Transplantation Registry Group (CBMTRG).

Journal: Science bulletin

Published: September 17, 2025

The clinical characteristics and prognosis analysis of acute B-cell lymphoblastic leukemia with MEF2D fusions.

The clinical characteristics and prognosis analysis of acute B-cell lymphoblastic leukemia with MEF2D fusions.

Journal: Annals of hematology

Published: August 19, 2025

Ruxolitinib as second-line therapy for bronchiolitis obliterans syndrome after hematopoietic cell transplantation: a retrospective multicenter study.

Ruxolitinib as second-line therapy for bronchiolitis obliterans syndrome after hematopoietic cell transplantation: a retrospective multicenter study.

Journal: Annals of hematology

Published: August 12, 2025

A phase 2 trial of a "sandwich" strategy: Sequential CD22/CD19 chimeric antigen receptor T-cells therapy combined with autologous hematopoietic stem cell transplantation in patients with Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia.

A phase 2 trial of a "sandwich" strategy: Sequential CD22/CD19 chimeric antigen receptor T-cells therapy combined with autologous hematopoietic stem cell transplantation in patients with Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia.

Journal: Cancer

Published: August 01, 2025

IL-6 knockdown anti-CD19 CAR-T cells (ssCART-19) for patients with relapsed or refractory acute lymphoblastic leukemia: phase 1 trial.

IL-6 knockdown anti-CD19 CAR-T cells (ssCART-19) for patients with relapsed or refractory acute lymphoblastic leukemia: phase 1 trial.

Journal: Blood cancer journal

Published: July 18, 2025

Phase II study of dual epigenetic targeting with chidamide and azacitidine in patients with high-risk acute myeloid leukemia after allo-HSCT.

Phase II study of dual epigenetic targeting with chidamide and azacitidine in patients with high-risk acute myeloid leukemia after allo-HSCT.

Journal: Clinical epigenetics

Published: June 08, 2025

Showing 1-12 of 302

Last Updated: 09/26/2026